United Advisor Group LLC Grows Stock Position in Pfizer Inc. $PFE

United Advisor Group LLC raised its position in Pfizer Inc. (NYSE:PFE) by 22.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,047 shares of the biopharmaceutical company’s stock after acquiring an additional 2,794 shares during the quarter. United Advisor Group LLC’s holdings in Pfizer were worth $365,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Pfizer by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the period. Geode Capital Management LLC grew its stake in shares of Pfizer by 1.4% during the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after acquiring an additional 1,820,634 shares in the last quarter. Northern Trust Corp increased its position in shares of Pfizer by 6.8% during the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares during the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after purchasing an additional 838,198 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on PFE. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Price Performance

PFE opened at $25.45 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $24.82 and its 200 day moving average price is $24.46. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The firm has a market cap of $144.70 billion, a price-to-earnings ratio of 13.54, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.